BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30468988)

  • 1. OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
    Towner RA; Smith N; Saunders D; Brown CA; Cai X; Ziegler J; Mallory S; Dozmorov MG; Coutinho De Souza P; Wiley G; Kim K; Kang S; Kong DS; Kim YT; Fung KM; Wren JD; Battiste J
    Transl Oncol; 2019 Feb; 12(2):320-335. PubMed ID: 30468988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
    Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
    J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera.
    Towner RA; Hocker J; Smith N; Saunders D; Battiste J; Hanas J
    Brain Sci; 2022 Jan; 12(1):. PubMed ID: 35053843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway.
    Zou Y; Xu L; Wang W; Zhu X; Lin J; Li H; Chen J; Xu W; Gao H; Wu X; Yin Z; Wang Q
    Phytomedicine; 2024 Jul; 129():155714. PubMed ID: 38723526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
    Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
    Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of decreased levels of lipopolysaccharide-binding protein with OKN-007-induced regression of tumor growth in an F98 rat glioma model.
    Smith N; Saunders D; Jensen RL; Towner RA
    J Neurosurg; 2019 Oct; 133(6):1695-1703. PubMed ID: 31628293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
    Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of m
    Li F; Chen S; Yu J; Gao Z; Sun Z; Yi Y; Long T; Zhang C; Li Y; Pan Y; Qin C; Long W; Liu Q; Zhao W
    Clin Transl Med; 2021 Sep; 11(9):e553. PubMed ID: 34586728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.